Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Schnorr

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Clinical Chemistry|May 20, 1998
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in bloodK Jung, C Laube, M Lein, et al.
Clinical Biochemistry|August 1, 1997
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in bloodM Lein, L Nowak, K Jung, et al.
Journal of Cancer Research and Clinical Oncology|March 14, 1998
Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balanceK Jung, B Friedrich, I Türk, et al.
The Prostate|February 18, 1998
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspectsK Jung, M Lein, N Ulbrich, et al.
Der Urologe. Ausg. A|February 28, 2003
[Laparoscopic radical nephrectomy: indications, techniques, and oncological outcome]A H Wille, J Roigas, S Deger, et al.
Urology|March 29, 2000
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulationC Stephan, K Jung, B Brux, et al.
Urology|April 18, 2001
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinomaS Gerhards, K Jung, F Koenig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000S Gerhards, K Jung, F Koenig, et al.
Anticancer Research|May 1, 2001
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosisM Lein, K Jung, U Elgeti, et al.
Clinical Chemistry|March 3, 1999
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasiaK Jung, B Brux, A Knäbich, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Clinical Chemistry|May 20, 1998
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in bloodK Jung, C Laube, M Lein, et al.
Clinical Biochemistry|August 1, 1997
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in bloodM Lein, L Nowak, K Jung, et al.
Journal of Cancer Research and Clinical Oncology|March 14, 1998
Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balanceK Jung, B Friedrich, I Türk, et al.
The Prostate|February 18, 1998
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspectsK Jung, M Lein, N Ulbrich, et al.
Der Urologe. Ausg. A|February 28, 2003
[Laparoscopic radical nephrectomy: indications, techniques, and oncological outcome]A H Wille, J Roigas, S Deger, et al.
Urology|March 29, 2000
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulationC Stephan, K Jung, B Brux, et al.
Urology|April 18, 2001
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinomaS Gerhards, K Jung, F Koenig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000S Gerhards, K Jung, F Koenig, et al.
Anticancer Research|May 1, 2001
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosisM Lein, K Jung, U Elgeti, et al.
Clinical Chemistry|March 3, 1999
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasiaK Jung, B Brux, A Knäbich, et al.
Pageof 12